Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents. 2019

Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
Medical Science Research Center, Zhongnan Hospital of Wuhan University, Hubei, Wuhan, 430071, PR China.

A series of new quinoline derivatives was designed, synthesized and evaluated as potential antitumor agents. The results indicated that most compounds exhibited potent antiproliferative activity, and 7-(4-fluorobenzyloxy)N-(2-(dimethylamino)- ethyl)quinolin-4-amine 10g was found to be the most potent antiproliferative agent against human tumor cell lines with an IC50 value of less than 1.0 μM. Preliminary structure-activity relationships analysis suggested that (1) the large and bulky alkoxy substituent in position-7 might be a beneficial pharmacophoric group for antiproliferative activity; (2) the amino side chain substituents in position-4 facilitated the antiproliferative activity of this class of compounds; and (3) the length of the alkylamino side chain moiety affected the antiproliferative potency, with two CH2 units being the most favorable. Further investigation of the mechanism of action of this class of compounds demonstrated that the representative compound 10g triggered p53/Bax-dependent colorectal cancer cell apoptosis by activating p53 transcriptional activity. Moreover, the results showed that compound 10g effectively inhibited tumor growth in a colorectal cancer xenograft model in nude mice. Thus, these quinoline derivatives might serve as candidates for the development of new antitumor drugs.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D011804 Quinolines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
September 2019, European journal of medicinal chemistry,
Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
February 2013, European journal of medicinal chemistry,
Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
July 2019, Archiv der Pharmazie,
Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
December 2002, Archives of pharmacal research,
Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
November 2013, European journal of medicinal chemistry,
Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
August 2014, European journal of medicinal chemistry,
Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
March 2018, European journal of medicinal chemistry,
Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
March 2021, Journal of natural products,
Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
March 2023, Bioorganic & medicinal chemistry,
Shangze Li, and Lihua Hu, and Jianru Li, and Jiongchang Zhu, and Feng Zeng, and Qiuhua Huang, and Liqin Qiu, and Runlei Du, and Rihui Cao
June 2017, MedChemComm,
Copied contents to your clipboard!